Novanta Inc. (NOVT)
| Market Cap | 4.93B +13.6% |
| Revenue (ttm) | 980.60M +3.3% |
| Net Income | 53.83M -16.0% |
| EPS | 1.47 -16.9% |
| Shares Out | 35.61M |
| PE Ratio | 94.09 |
| Forward PE | 38.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 466,628 |
| Open | 136.77 |
| Previous Close | 136.28 |
| Day's Range | 134.92 - 139.38 |
| 52-Week Range | 98.27 - 149.95 |
| Beta | 1.62 |
| Analysts | Buy |
| Price Target | 144.00 (+4.11%) |
| Earnings Date | May 11, 2026 |
About NOVT
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment s... [Read more]
Financial Performance
In 2025, Novanta's revenue was $980.60 million, an increase of 3.30% compared to the previous year's $949.25 million. Earnings were $53.83 million, a decrease of -16.01%.
Financial StatementsAnalyst Summary
According to one analyst, the rating for NOVT stock is "Buy" and the 12-month stock price target is $144.0.
News
Novanta Inc. Announces Schedule of First Quarter 2026 Earnings Release and Conference Call
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its first quarter 2026 resul...
Novanta upgraded to Outperform from Neutral at Baird
Baird analyst Quinn Fredrickson upgraded Novanta (NOVT) to Outperform from Neutral with a price target of $144, down from $150. The firm remains positive on the advanced industrial technology group,
Novanta Joins NVIDIA Halos AI Systems Inspection Lab
BOSTON--(BUSINESS WIRE)--Novanta Inc. (NASDAQ: NOVT) announced today that it has joined NVIDIA Halos AI Systems Inspection Lab, the first ANSI National Accreditation Board (ANAB) accredited inspection...
Novanta price target raised to $150 from $138 at Baird
Baird analyst Robert Mason raised the firm’s price target on Novanta (NOVT) to $150 from $138 and keeps a Neutral rating on the shares. The firm updated its model following
Novanta Earnings Call Transcript: Q4 2025
Record 2025 revenue and bookings, strong new product growth, and double-digit profit gains were achieved, though margins and cash flow were temporarily pressured by manufacturing transitions. 2026 guidance calls for 4–6% organic growth, margin expansion, and robust acquisition capacity.
Novanta reports Q4 adjusted EPS 91c, consensus 88c
Reports Q4 revenue $258M, consensus $260.72M. “Novanta (NOVT) exceeded expectations for revenue in the fourth quarter, delivering accelerated reported growth of 9% and a return to positive organic gro...
Novanta sees Q1 adjusted EPS 75c-80c, consensus 83c
Sees Q1 revenue $250M-$255M, consensus $253.32M.
Novanta sees 2026 adjusted EPS $3.50-$3.65, consensus $3.61
Sees 2026 revenue $1.03B-$1.05B, consensus $1.04B.
Novanta Announces Financial Results for the Fourth Quarter and Full Year 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial res...
Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, February 24, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its fourth quarter 2025 resu...
Novanta to Present at the CJS Securities 26th Annual New Ideas for the New Year Investor Conference on Wednesday, January 14, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Chuck Ravetto, Chief...
Novanta to Present at the J.P. Morgan 44th Annual Healthcare Conference on Wednesday, January 14, 2026
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Ch...
Novanta Inc. Announces Pricing of $550,000,000 Tangible Equity Units Offering
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) ("Novanta" or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has ...
Novanta announces offering of 11M tangible equity units
Novanta (NOVT) announced that it has commenced a public offering of 11M tangible equity units, with an aggregate stated amount of $550M. Each tangible equity unit will have a stated
Novanta Inc. Announces Offering of Tangible Equity Units
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) ("Novanta" or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has ...
Novanta Earnings Call Transcript: Q3 2025
Q3 2025 results exceeded expectations with record revenue, strong margin expansion, and robust new product growth. Guidance calls for sequential revenue and profit growth into Q4 and 2026, led by advanced surgery and robotics, with regional manufacturing and acquisitions supporting resilience.
Novanta reports Q3 adjusted EPS 87c, consensus 82c
Reports Q3 revenue $247.8M, consensus $245.95M. “We exceeded our expectations for revenue, profit and Adjusted EPS growth in the third quarter, based on improving business fundamentals, strength of co...
Novanta sees Q4 adjusted EPS 87c-93c, consensus 94c
Sees Q4 revenue $253M-$257M, consensus $255.17M.
Novanta narrows FY25 adjusted EPS $3.24-$3.30 from $3.22-$3.36
Consensus $3.26. Narrows FY25 revenue view to $975M-$979M from $970M-$985M, consensus $975.56M.
Novanta Announces Financial Results for the Third Quarter 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial res...
Novanta to Present at Jefferies Global Healthcare Conference on Tuesday, November 18, 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Ch...
Novanta Hosts ISO event for Humanoid Robot Safety Standards
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT), a trusted technology partner to medical and advanced industrial OEMs, announced that it will host an International Organization for Standardizatio...
Novanta to Present at the Baird 2025 Global Industrial Conference on Tuesday, November 11, 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Ch...
Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, November 4, 2025
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2025 resul...
Novanta announces additional $200M share repurchase program authorization
Novanta (NOVT) announced that its board of directors has authorized the repurchase of up to an additional $200M of the company’s outstanding common shares, adding capacity to the $31M remaining